None

Celltrion CEO Cites Pfizer, J&J and Sanofi As Potential Buyers For Biosimilars Business

Although Korea’s Celltrion is not in takeover talks yet, CEO Seo Jung-jin named potential buyers after announcing he would sell his stake in the company he founded. Celltrion is expecting approval s...

Celltrion CEO Cites Pfizer, J&J and Sanofi As Potential Buyers For Biosimilars Business

Although Korea’s Celltrion is not in takeover talks yet, CEO Seo Jung-jin named potential buyers after announcing he would sell his stake in the company he founded. Celltrion is expecting approval s...

Let The Games Begin: Celltrion Sets Sights On Global Markets After Approval Of Remicade Biosimilar In Korea

In addition to Remicade, Celltrion has seven other biosimilars in development, including versions of Roche’s MabThera and Herceptin.

Celltrion Sale Problems Said Due To Trust In Company, Sources Say

Celltrion founder Seo Jung-jin recently offered for sale his controlling stake in an effort to prevent stock market manipulation of his attempt to sell it, but that has not saved a dive in its perceiv...

South Korea's Celltrion sale seen slow-going as sceptics emerge

SEOUL, May 15 (Reuters) - Fed up with fighting what he called a costly battle with short-sellers that punished its stock, Celltrion Inc's founder Seo Jung-jin has put his controlling stake in the Sout...

Biosimilars For Sale: Korea’s Celltrion Seeks MNC Buyer

The founder of Celltrion, Korea’s biosimilars frontrunner, told local press April 16 he would sell his controlling stake in the holding vehicle for the company to a multinational drug company.

Korea’s Celltrion Looks To Help Patients Pay For Remicade Biosimilar

Although the price of Celltrion’s biosimilar is lower than J&J’s Remicade, most patients will not be covered under Korea’s National Health Insurance.

Celltrion stops phase III trial of biosimilar rituximab

South Korean biotechnology company Celltrion has stopped the late-stage trial of its biosimilar version of Roche’s blockbuster arthritis/non-Hodgkin’s lymphoma drug MabThera/Rituxan (rituximab).

None